Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 19;11(5):513–522. doi: 10.1111/cts.12569

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of Society for Clinical and Translational Science and Association for Patient Oriented Research

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Quantitative profile of circulating testosterone (T) and its primary and secondary metabolites in pooled serum from control eugonadal subjects (n = 7) (before acyline dose, baseline) (a) and pools of all time‐points after single oral dose of testosterone at 200 mg (n = 7) (T200) (b) and 800 mg (n = 7) (T800) (c). Although the study was conducted with 200, 400, and 800 mg testosterone dose, only T200 and T800 were quantified. The table (d) represents fold change in the respective metabolites at T200 and T800 in experimental hypogonadism subjects as compared with the eugonadal subjects. Glucuronides (TG, AG, and EtioG) are the major circulating metabolites. AED, androstenedione; AG, androsterone glucuronide; DHT, dihydrotestosterone; DHTG, dihydrotestosterone glucuronide; EtioG, etiocholanolone glucuronide; T, testosterone; TG, testosterone glucuronide.